Roche's Phase 3 Study on Polivy With Chemotherapy Regimen Met Primary Endpoint

By Giulia Petroni

Roche Holding AG on Monday said that its phase 3 study on the use of Polivy in combination with chemotherapy regimen R-CHP for the treatment of diffuse large B-cell lymphoma met its primary endpoint.

The Swiss pharmaceutical giant said the trial showed the use of polatuzumab vedotin with rituximab plus cyclophosphamide, doxorubicin and prednisone significantly improves outcomes in patients with a previously untreated aggressive form of lymphoma compared with standard of care.

Roche said results of the study will be submitted to health authorities.

Write to Giulia Petroni at [e-mail]

(END) Dow Jones Newswires

08-09-21 0243ET